Clinical Trial Update: QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of the NANT pancreatic cancer vaccine by ImmunityBio, in patients who progressed on or after standard therapy, has been terminated with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• NANT Pancreatic Cancer Vaccine

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-12-12